Clindamycin Phosphate Topical Solution USP, 1%, packaged in a) 30 mL applicator bottles (NDC 0472...

FDA Drug Recall #D-0519-2017 — Class III — February 28, 2017

Recall Summary

Recall Number D-0519-2017
Classification Class III — Low risk
Date Initiated February 28, 2017
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm G & W Laboratories, Inc.
Location South Plainfield, NJ
Product Type Drugs
Quantity 39,816 bottles

Product Description

Clindamycin Phosphate Topical Solution USP, 1%, packaged in a) 30 mL applicator bottles (NDC 0472-0987-91) and b) 60 mL applicator bottles (NDC 0472-0987-92), Rx Only, Manufactured by: G&W Laboratories, Inc., 111 Coolidge Street, South Plainfield, NJ 07080; Distributed by: Actavis Mid Atlantic LLC, 1877 Kawai Road, Lincolnton, NC 28092.

Reason for Recall

CGMP Deviations: an expired active ingredient was used in the manufacture of these recalled lots.

Distribution Pattern

Nationwide in the USA.

Lot / Code Information

Lot #'s: a) 032100042, 032100043, 032100044, 032100045, Exp 06/17; b) 032100038, 032100039, 032100040, 032100041, Exp 05/17; 032100046, 032100047, 032100048, 032100049, Exp 06/17.

Other Recalls from G & W Laboratories, Inc.

Recall # Classification Product Date
D-0250-2018 Class III Ciclopirox Olamine Cream USP, 0.77%, packaged i... Jan 19, 2018
D-0945-2017 Class III G & W Clobetasol Propionate Ointment 0.05%, pac... Jun 2, 2017
D-0636-2017 Class III Ciclopirox Olamine Cream USP, 0.77%, packaged i... Mar 20, 2017
D-0501-2017 Class II Indocin (Indomethacin) suppositories, USP, 50 m... Feb 7, 2017

Frequently Asked Questions

cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.